Oncology nurses should understand the evolving therapeutic options available and the side effects related to those treatments as well as the current guidelines in the context of the patient's previous therapy and disease history to navigate the various options available.

Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.

Clinicians must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.

Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.

Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.

To optimize patient outcomes, clinicians need to understand the risks and benefits of early intervention for smoldering multiple myeloma based on risk stratification and the importance of enrolling patients in clinical trials examining early intervention.

Health care providers need education about how to individualize treatment plans in this complex environment to help them make the best decisions in their own practices and improve the outcomes of patients with newly diagnosed as well as those with relapsed/refractory multiple myeloma.